Evidence map›Paper›PMID 37142297›Full record

ArticleBMJ global health2023

How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008-2017.

Kathryn L Zoerhoff, Pamela S Mbabazi, Katherine Gass, John Kraemer, Brian B Fuller, Lynsey Blair, Roland Bougma, Aboulaye Meite, Nebiyu Negussu, Bizuayehu Gashaw and 24 more

Open access · goldAbstract read
In one paragraph

Article in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 13 countries.

Kathryn L ZoerhoffInternational Development Group, RTI International, Washington, District of Columbia, USA.
Pamela S MbabaziWorld Health Organization, Geneva, Switzerland.
Katherine GassThe Task Force for Global Health, Decatur, Georgia, USA.
John KraemerSchool of Health, Georgetown University, Washington, District of Columbia, USA.
Brian B FullerInternational Development Group, RTI International, Washington, District of Columbia, USA.ORCID 0000-0001-5865-2528
Lynsey BlairSCI Foundation, London, UK.
Roland BougmaMinistère de la Santé et de l'Hygiène Publique, Ouagadougou, Burkina Faso.
Aboulaye MeiteMinistère de la Santé et de l'Hygiène Publique, Abidjan, Côte d'Ivoire.
Nebiyu NegussuFederal Ministry of Health, Addis Ababa, Addis Ababa, Ethiopia.
Bizuayehu GashawBahir Dar University, Bahir Dar, Amhara, Ethiopia.
Scott D NashThe Carter Center, Atlanta, Georgia, USA.
Nana-Kwadwo BiritwumMinistry of Health, Accra, Ghana.
Jean Frantz LemoineMinistère de la Santé Publique et de la Population, Port-au-Prince, Haiti.
Helena Ullyartha PangaribuanMinistry of Health, Jakarta, Indonesia.
Eksi WijayantiMinistry of Health, Jakarta, Indonesia.
Karsor KollieMinistry of Health, Monrovia, Liberia.
Clara Fabienne RasoamanamihajaMinistère de la Santé Publique, Antananarivo, Madagascar.
Lazarus JuziweloMinistry of Health, Lilongwe, Malawi.
Square MkwandaMinistry of Health, Lilongwe, Malawi.
Pradip RimalMinistry of Health and Population, Kathmandu, Nepal.
Issa GnandouMinistère de la Santé Publique, de la Population, et des Affaires Sociales, Niamey, Niger.
Bocar DiopMinistère de la Santé et de l'Action Sociale, Dakar, Senegal.
Ameyo Monique DorkenooMinistère de la Santé, de l'Hygiène Publique, et de l'Accès Universel aux Soins, Lomé, Togo.
Rachel BronzanFHI 360, Washington, District of Columbia, USA.
Edridah Muheki TukahebwaMinistry of Health, Kampala, Uganda.
Fatima KaboleZanzibar Ministry of Health, Stone Town, Tanzania, United Republic of.
Violetta YevstigneyevaUSAID, Washington, District of Columbia, USA.
Donal BisanzioInternational Development Group, RTI International, Washington, District of Columbia, USA.
Lauren CourtneyInternational Development Group, RTI International, Washington, District of Columbia, USA.
Joseph KoromaFHI 360, Washington, District of Columbia, USA.
Egide EndayishimyeFHI 360, Washington, District of Columbia, USA.
Richard ReithingerInternational Development Group, RTI International, Washington, District of Columbia, USA rreithinger@yahoo.co.uk.ORCID 0000-0001-5710-1556
Margaret C BakerInternational Development Group, RTI International, Washington, District of Columbia, USA.
Fiona M FlemingSCI Foundation, London, UK.
RTI International · USFamily Health International 360 · USMinistry of Health · IDMinistry of Health · MWBahir Dar University · ETCarter Center · USFederal Ministry of Health · ETGeorgetown University · USHelen Keller International · USMinistère De La Santé · BFMinistère de la Santé et de l'Hygiène Publique · CIMinistère de la Santé Publique · NEMinistère de la Santé Publique et Action Sociale · SNMinistry of Health · UGMinistry of Health · GHMinistry of Health and Population · NPThe Task Force for Global Health · USTogolese Ministry of Health · TGUnited States Agency for International Development · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionDelivering preventive chemotherapy through mass drug administration (MDA) is a central approach in controlling or eliminating several neglected tropical diseases (NTDs). Treatment coverage, a primary indicator of MDA performance, can be measured through routinely reported programmatic data or population-based coverage evaluation surveys. Reported coverage is often the easiest and least expensive way to estimate coverage; however, it is prone to inaccuracies due to errors in data compilation and imprecise denominators, and in some cases measures treatments offered as opposed to treatments swallowed.

objectiveAnalyses presented here aimed to understand (1) how often coverage calculated using routinely reported data and survey data would lead programme managers to make the same programmatic decisions; (2) the magnitude and direction of the difference between these two estimates, and (3) whether there is meaningful variation by region, age group or country.

methodsWe analysed and compared reported and surveyed treatment coverage data from 214 MDAs implemented between 2008 and 2017 in 15 countries in Africa, Asia and the Caribbean. Routinely reported treatment coverage was compiled using data reported by national NTD programmes to donors, either directly or via NTD implementing partners, following the implementation of a district-level MDA campaign; coverage was calculated by dividing the number of individuals treated by a population value, which is typically based on national census projections and occasionally community registers. Surveyed treatment coverage came from post-MDA community-based coverage evaluation surveys, which were conducted as per standardised WHO recommended methodology.

resultsCoverage estimates using routine reporting and surveys gave the same result in terms of whether the minimum coverage threshold was reached in 72% of the MDAs surveyed in the Africa region and in 52% in the Asia region. The reported coverage value was within ±10 percentage points of the surveyed coverage value in 58/124 of the surveyed MDAs in the Africa region and 19/77 in the Asia region. Concordance between routinely reported and surveyed coverage estimates was 64% for the total population and 72% for school-age children. The study data showed variation across countries in the number of surveys conducted as well as the frequency with which there was concordance between the two coverage estimates.

conclusionsProgramme managers must grapple with making decisions based on imperfect information, balancing needs for accuracy with cost and available capacity. The study shows that for many of the MDAs surveyed, based on the concordance with respect to reaching the minimum coverage thresholds, the routinely reported data were accurate enough to make programmatic decisions. Where coverage surveys do show a need to improve accuracy of routinely reported results, NTD programme managers should use various tools and approaches to strengthen data quality in order to use data for decision-making to achieve NTD control and elimination goals.

Indexed as

Elephantiasis, FilarialMass Drug AdministrationAfricaChildHumansNeglected DiseasesSurveys and Questionnairesfilariasisintervention studyonchocerciasispublic healthtrachoma

Identifiers

PMID37142297
PMCPMC10163531
OpenAlexW4372332075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.